# EDGAR Filing Document

**Accession Number:** 0001674241
**File Stem:** 0001193125-25-289897
**Filing Date:** 2025-11
**Character Count:** 6928
**Document Hash:** cfe66a4379f4e95d509806afc41d7ea2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-289897.hdr.sgml**: 20251120

**ACCESSION NUMBER**: 0001193125-25-289897

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251120

**DATE AS OF CHANGE**: 20251120

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IMMUCELL CORP /DE/
- **CENTRAL INDEX KEY:** 0000811641
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 010382980
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-39373
- **FILM NUMBER:** 251503525

**BUSINESS ADDRESS:**
- **STREET 1:** 56 EVERGREEN DR
- **CITY:** PORTLAND
- **STATE:** ME
- **ZIP:** 04103
- **BUSINESS PHONE:** 2078782770

**MAIL ADDRESS:**
- **STREET 1:** 56 EVERGREEN DRIVE
- **CITY:** PORTLAND
- **STATE:** ME
- **ZIP:** 04103
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Knudsen Ejnar A III
- **CENTRAL INDEX KEY:** 0001674241

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** 1811 AKSARBEN DRIVE
- **CITY:** OMAHA
- **STATE:** NE
- **ZIP:** 68106

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**ImmuCell Corporation**

*(Name of Issuer)*

**Common Stock, $0.10 par value per share**

*(Title of Class of Securities)*

**045252306**

*(CUSIP Number)*

**Ejnar A. Knudsen III**<br>212 West Superior<br>Suite 500<br>Chicago IL 60654<br>(530) 564-0626

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**11/19/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **045252306** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Ejnar A. Knudsen III** | Name of reporting person<br>**Ejnar A. Knudsen III** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**465790.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**367000.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**465790.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**367000.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**832790.00** | Aggregate amount beneficially owned by each reporting person<br>**832790.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.21%** | Percent of class represented by amount in Row (11)<br>**9.21%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, $0.10 par value per share

**(b) Name of Issuer:**
ImmuCell Corporation

**(c) Address of Issuer's Principal Executive Offices:**
56 Evergreen Drive, Portland, ME, 04103

**Item 4. Purpose of Transaction**

All shares held by the Reporting Person are held by the Reporting Person for investment purposes.
The Reporting Person currently has no plans or proposals that relate to, or would result in, any of the matters described in subsections (a) through (j) of Item 4 of the instructions to Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
832,790; 9.21% (based on the outstanding number of shares reported as being outstanding as of October 31, 2025 in the Quarterly Report on Form 10-Q of ImmuCell Corporation (the "Company") filed with the Securities and Exchange Commission on November 11, 2025)

**(b)**
The Reporting Person has sole voting power and sole dispositive power with respect to 465,790 shares of the Company's common stock.  The Reporting Person has shared voting power and shared dispositive power with respect to 367,000 shares of the Company's common stock.

**(c)**
As of the date hereof, the Reporting Person is the beneficial owner of 832,790 shares of common stock representing approximately 9.21% of the approximately 9,045,851 shares outstanding, as disclosed in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2025.  The Reporting Person's beneficial ownership consists of 465,790 shares of common stock of the Company over which the Reporting Person has sole voting power and sole dispositive power.  These shares are held directly by the Reporting Person or indirectly by entities the Reporting Person controls. Craton is the record owner of 367,000 shares the Company's common stock.  The compulsory redemption of the limited partners of Craton resulted in Knudsen having an increased ownership in the remaining securities, including the Company.  Knudsen has an interest in Craton's general partner and is the direct or indirect owner of various family limited partner accounts remaining with Craton.  Knudsen and Raju Shah are the only remaining partners of Craton.  Knudsen may be considered to share the power to vote or direct the vote of, and the power to dispose or direct the disposition of, 367,000 shares of the Company's common stock owned of record by Craton. This statement on Schedule 13D shall not be construed as an admission that any Reporting Person is the beneficial owner of the securities covered by this statement.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Not applicable.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Ejnar A. Knudsen III

**Signature:** /s/ Ejnar A. Knudsen III

**Name/Title:** Ejnar A. Knudsen III

**Date:** 11/20/2025